Tournoy K G, Maddens S, Gosselin R, Van Maele G, van Meerbeeck J P, Kelles A
Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Thorax. 2007 Aug;62(8):696-701. doi: 10.1136/thx.2006.072959.
Staging of non-small cell lung cancer (NSCLC) is important for determining choice of treatment and prognosis. The accuracy of FDG-PET scans for staging of lymph nodes is too low to replace invasive nodal staging. It is unknown whether the accuracy of integrated FDG-PET/CT scanning makes invasive staging redundant.
In a prospective study, the mediastinal and/or hilar lymph nodes in patients with proven NSCLC were investigated with integrated FDG-PET/CT scanning. Pathological confirmation of all suspect lymph nodes was obtained to calculate the accuracy of the fusion images. In addition, the use of the standardised uptake value (SUV) in the staging of intrathoracic lymph nodes was analysed.
105 intrathoracic lymph node stations from 52 patients with NSCLC were characterised. The prevalence of malignancy in the lymph nodes was 36%. The sensitivity of the integrated FDG-PET/CT scan to detect malignant lymph nodes was 84% and its specificity was 85% (positive likelihood ratio 5.64, negative likelihood ratio 0.19). SUV(max), SUV(mean) and the SUV(max)/SUV(liver) ratio were all significantly higher in malignant than in benign lymph nodes. The area under the receiver operating curve did not differ between these three quantitative variables, but the highest accuracy was found with the SUV(max)/SUV(liver) ratio. At a cut-off value of 1.5 for the SUV(max)/SUV(liver )ratio, the sensitivity and specificity to detect malignant lymph node invasion were 82% and 93%, respectively.
The accuracy of integrated FDG-PET/CT scanning is too low to replace invasive intrathoracic lymph node staging in patients with NSCLC. The visual interpretation of the fusion images of the integrated FDG-PET/CT scan can be replaced by the quantitative variable SUV(max)/SUV(liver) without loss of accuracy for intrathoracic lymph node staging.
非小细胞肺癌(NSCLC)的分期对于确定治疗方案的选择和预后至关重要。FDG-PET扫描用于淋巴结分期的准确性过低,无法替代侵入性淋巴结分期。目前尚不清楚FDG-PET/CT联合扫描的准确性是否会使侵入性分期变得多余。
在一项前瞻性研究中,对经证实患有NSCLC的患者的纵隔和/或肺门淋巴结进行了FDG-PET/CT联合扫描。对所有可疑淋巴结进行病理确认,以计算融合图像的准确性。此外,还分析了标准化摄取值(SUV)在胸内淋巴结分期中的应用。
对52例NSCLC患者的105个胸内淋巴结站进行了特征分析。淋巴结中恶性肿瘤的患病率为36%。FDG-PET/CT联合扫描检测恶性淋巴结的敏感性为84%,特异性为85%(阳性似然比5.64,阴性似然比0.19)。恶性淋巴结的SUV(最大值)、SUV(平均值)和SUV(最大值)/SUV(肝脏)比值均显著高于良性淋巴结。这三个定量变量的受试者工作特征曲线下面积无差异,但SUV(最大值)/SUV(肝脏)比值的准确性最高。当SUV(最大值)/SUV(肝脏)比值的截断值为1.5时,检测恶性淋巴结侵犯的敏感性和特异性分别为82%和93%。
FDG-PET/CT联合扫描的准确性过低,无法替代NSCLC患者的侵入性胸内淋巴结分期。FDG-PET/CT联合扫描融合图像的视觉解读可以用定量变量SUV(最大值)/SUV(肝脏)替代,而不会损失胸内淋巴结分期的准确性。